Differing Perspectives on Roche/Genentech Biologic Manufacturing
This article was originally published in RPM Report
Executive Summary
FDA has raised questions about manufacturing and quality control during the review of two recently approved Roche/Genentech cancer drugs. At the same time, Roche is highlighting its leading presence and competency in biologics manufacturing as a core asset for the company.
You may also be interested in...
A Consent Decree By Other Means?
Here is the list of manufacturing commitments Roche/Genentech accepted to receive approval of Kadcyla (T-DM1, ado-trastuzumab emtansine). FDA's redactions are designated with brackets.
Genentech’s Cancer Product Line Expands, As Do Its Post-Market Manufacturing Obligations
Genentech appears to be having significant manufacturing problems for some of its new cancer therapies. FDA hasn’t taken enforcement action yet, but the agency has delayed two approvals and tied them to post-market requirements to address QC issues.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.